Boulle N, Logié A, Gicquel C, Perin L, Le Bouc Y
Laboratoire d'Explorations Fonctionnelles Endocriniennes, Hôpital Trousseau, Paris, France.
J Clin Endocrinol Metab. 1998 May;83(5):1713-20. doi: 10.1210/jcem.83.5.4816.
In adrenocortical tumors, malignancy is strongly associated with insulin-like growth factor II (IGF-II) gene overexpression and abnormalities at the 11p15 locus, suggesting a role for this growth factor in adrenocortical tumorigenesis. To further investigate this role, the IGF/IGF-binding protein (IGFBP) system was analyzed in 18 adrenocortical tumors, classified into 2 groups on the basis of their IGF-II messenger ribonucleic acid (mRNA) content (group 1, normal IGF-II mRNA content, mostly benign tumors; group 2, high IGF-II mRNA content, mostly malignant tumors). Group 2 tumors contained 10 times more IGF-II protein than group 1 tumors or normal adrenal tissue (P < 0.001), indicating efficient translation of IGF-II mRNA in malignant tumors. Western ligand blotting detected various functional IGFBPs in normal adrenocortical glands and tumors: a doublet of 39-42 kDa identified by immunoblotting as IGFBP-3, a band at 32 kDa, and bands at 29-30 and 24 kDa. Total IGFBP-3 protein levels were similar in the two groups of tumors. By contrast, malignant tumors differed from benign ones by specific expression of the 32-kDa IGFBP. Immunoblotting identified this 32-kDa band together with a proteolytic fragment of 25 kDa as IGFBP-2, and quantitative analysis showed significantly higher levels of total IGFBP-2 in malignant tumors than in benign tumors (P < 0.001). Despite enhanced levels of IGBP-2 protein in malignant tumors, no increase in IGFBP-2 mRNA levels was detected, suggesting post-transcriptional regulation of this IGFBP. These results confirm the major role of IGF-II in adrenocortical tumorigenesis and suggest that IGFBP-2 may be a regulator of IGF-II proliferative effects in this tumor system.
在肾上腺皮质肿瘤中,恶性肿瘤与胰岛素样生长因子II(IGF-II)基因过表达及11p15位点异常密切相关,提示该生长因子在肾上腺皮质肿瘤发生过程中发挥作用。为进一步研究此作用,对18例肾上腺皮质肿瘤的IGF/IGF结合蛋白(IGFBP)系统进行了分析,根据其IGF-II信使核糖核酸(mRNA)含量分为2组(第1组,IGF-II mRNA含量正常,大多为良性肿瘤;第2组,IGF-II mRNA含量高,大多为恶性肿瘤)。第2组肿瘤中IGF-II蛋白含量比第1组肿瘤或正常肾上腺组织高10倍(P < 0.001),表明恶性肿瘤中IGF-II mRNA有效翻译。Western配体印迹法在正常肾上腺皮质及肿瘤中检测到多种功能性IGFBP:经免疫印迹法鉴定为IGFBP-3的39 - 42 kDa双峰、32 kDa条带以及29 - 30 kDa和24 kDa条带。两组肿瘤中总IGFBP-3蛋白水平相似。相比之下,恶性肿瘤与良性肿瘤的区别在于32 kDa IGFBP的特异性表达。免疫印迹法将此32 kDa条带及25 kDa蛋白水解片段鉴定为IGFBP-2,定量分析显示恶性肿瘤中总IGFBP-2水平显著高于良性肿瘤(P < 0.001)。尽管恶性肿瘤中IGBP-2蛋白水平升高,但未检测到IGFBP-2 mRNA水平增加,提示该IGFBP存在转录后调控。这些结果证实了IGF-II在肾上腺皮质肿瘤发生中的主要作用,并提示IGFBP-2可能是该肿瘤系统中IGF-II增殖效应的调节因子。